An observational study in MALT Lymphoma, sponsored by International Extranodal Lymphoma Study Group (IELSG). Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by International Extranodal Lymphoma Study Group (IELSG) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Lymphoma, B-Cell, Marginal Zone by International Extranodal Lymphoma Study Group (IELSG) — 2 open to participants now, 6 under way, none of them phase 3. Lymphoma, B-Cell, Marginal Zone · International Extranodal Lymphoma Study Group (IELSG).
Among the 12 studies in Lymphoma, B-Cell, Marginal Zone by International Extranodal Lymphoma Study Group (IELSG), this one is the only one that started in 2027, is one of 3 observational ones, and was the 12th registered.
877 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 113 are open to participants now.
Browse Lymphoma, B-Cell, Marginal Zone studies →2 of the 12 studies in Lymphoma, B-Cell, Marginal Zone by International Extranodal Lymphoma Study Group (IELSG) are open now, in 12 countries. Recruiting first, the newest first:
International Extranodal Lymphoma Study Group (IELSG) · Sites in United States, Argentina, Armenia and 12 more countries
Ages 18+
By country, each count listing its studies:
Of the 93 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 78 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 168 across 65 observational studies indexed under Lymphoma, B-Cell, Marginal Zone.
Median enrollment 44 across the 9 interventional studies, 400 across the 3 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
International Extranodal Lymphoma Study Group (IELSG) is the lead sponsor of 30 studies on the registry; 4 are open to participants now.
4 of the studies in Lymphoma, B-Cell, Marginal Zone by International Extranodal Lymphoma Study Group (IELSG) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05700149International Extranodal Lymphoma Study Group (IELSG)Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma | 2026-12-31 |
| NCT04333524International Extranodal Lymphoma Study Group (IELSG)FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role | 2027-02-15 |
| NCT03697512International Extranodal Lymphoma Study Group (IELSG)MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas | 2027-06-15 |
| NCT04646395International Extranodal Lymphoma Study Group (IELSG)Study of Acalabrutinib and Tafasitamab in MZL Patients | 2027-09-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 12 studies in Lymphoma, B-Cell, Marginal Zone by International Extranodal Lymphoma Study Group (IELSG), from their registry updates:
This tab as a report to print or save as PDF → With an account.
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is an slow growing malignancy characterized by marked biological and clinical differences across different anatomical sites.
Using participants' samples and clinical information, this observational and non-interventional research aims to generate a comprehensive molecular and cellular atlas of MALT lymphoma. The results will enable the identification of biologically meaningful tumor subtypes, microenvironmental niches, and candidate biomarkers with potential relevance for the diagnosis, prognosis, and therapy of MALT lymphoma.
Already existing and coded tumor biological material and health-related patient data will be retrospectively collected from institutional biobanks and patients' charts or electronic medical records upon receipt of ethical approval. Each patient enrolled in the study will be assigned a unique identification numerical code upon registration in the study. The unique identification code will be used to record health-related data and to label biological samples. The coded biological material will be transferred to the coordinating center at the Institute of Oncology Research (IOR) in Bellinzona. Health-related data will be collected in the electronic case report form (eCRF) (OpenClinica). Data quality will be ensured by query generation.
Annotated baseline features will include the date of diagnosis, date of biopsy, age, gender, Eastern Cooperative Oncology Group Performance Status (ECOG PS), Ann Arbor stage, lactate dehydrogenase (LDH), number and location of extranodal sites, bone marrow involvement and percentage, peripheral blood involvement, number of nodal sites, B symptoms, lymph nodes larger than 7 cm, hemoglobin (Hb), platelets, lymphocytes, beta-2-microglobulin, albumin, infections (hepatitis C virus, Helicobacter pylori, Chlamydophila psittaci, Achromobacter xylosoxidans, Campylobacter jejuni), serum paraprotein presence and type.
Annotated follow-up features included the date of progression to a disease requiring treatment, type of first-line treatment, date of start of the first line treatment, date of progression after first line treatment, date of the second line treatment, type of second line treatment, date of transformation, date of death, cause of death, and date of last follow-up. Mutation analysis, immunoglobulin genes and T cell receptor rearrangement analysis, copy number aberration analysis, structural variant analysis, and deoxyribonucleic acid (DNA) methylation profile will be performed by next-generation sequencing of genomic DNA extracted from the biopsy. Gene expression will be assessed by next-generation sequencing of RNA extracted from the biopsy. Protein expression will be assessed by mass spectrometry of proteins extracted from the biopsy. AI-based computational pathology will be performed on digitized whole-slide images of the biopsy to extract quantitative histologic features.
Single-cell transcriptomic profiling will be used to resolve intratumoral heterogeneity and to define malignant and non-malignant cellular populations. After quality control, normalization, and batch correction, unsupervised clustering will be applied to identify transcriptionally distinct cell states. Malignant B-cell populations will be distinguished from reactive B cells using a combination of copy number inference, immunoglobulin expression patterns, and canonical marker genes. Differential expression and pathway enrichment analyses will be conducted to identify signaling programs associated with anatomical site, immune context, and disease features.
In details:
Cross-modal integration will be performed using established computational frameworks to generate unified cell state annotations and pathway activity scores. Comparative analyses across anatomical sites will be a central assessment. Conserved versus site-specific cellular states, immune compositions, and signaling pathways will be systematically evaluated to identify shared disease mechanisms as well as context-dependent features. Associations with clinical variables (e.g., site of origin, prior treatment, disease stage) will be explored in an exploratory, hypothesis-generating manner.
All analyses will follow reproducible computational workflows with stringent quality control, appropriate correction for technical confounders, and transparent reporting of limitations. The resulting datasets and analytical outputs will provide an integrated molecular and spatial reference framework for MALT lymphoma, supporting downstream biomarker discovery and future translational studies.
Adult patients with diagnosis of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue on histology after Jan 1st, 2000
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Molecular and spatial profiles of MALT lymphoma
Generation of high-resolution molecular and spatial profiles of MALT lymphoma tissues, including annotation of malignant and non-malignant cell populations.
Time frame: 6 months: from the end of samples collection to the end of study analysis
Creation of a curated multi-omics dataset
Identification of spatial tumor-immune interactions, characterization of BCR/TCR clonality, derivation of molecular signatures associated with anatomical site and microenvironment, and creation of a curated multi-omics dataset suitable for deposition in controlled-access repositories
Time frame: 6 months: from the end of samples collection to the end of study analysis
Extraction of clinically relevant features using artificial intelligence (AI) from histology sections
Time frame: 6 months: from the end of samples collection to the end of study analysis
Plan to share: Yes — Processed molecular data, including single-cell and spatial transcriptomic matrices, cell type annotations, and derived pathway activity scores, will be made available to the scientific community through established public repositories (e.g. GEO, ArrayExpress, or Zenodo), such as controlled-access archives for human genomics data, once primary analyses and initial publications are completed.
Supporting information: Study protocol, Clinical study report
Time frame: From March 2029 to March 2035
Access criteria: Raw sequencing data will be deposited where permitted by consent and regulatory frameworks or otherwise shared in controlled-access form to qualified researchers upon reasonable request. Analysis code, computational workflows, and documentation will be shared via publicly accessible version-controlled repositories to ensure transparency and reproducibility
No publications or documents are linked to this record.
Start is estimated for Apr 2027; primary completion for Dec 2029, 32 months later.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Apr 2027, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphoma, B-Cell, Marginal Zone →
International Extranodal Lymphoma Study Group (IELSG)